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Biliary drainage in malignant biliary obstruction improves patient survival and quality of life. Although bypass surgery was historically the main method
of treating malignant biliary obstruction, stent insertion using endoscopy or interventional radiology is currently recognized as the ﬁrst-line of treatment.
Biliary stents have undergone various modiﬁcations in terms of material and structure, with the aim of increasing stent patency. One such modiﬁcation is
the antitumor-agent-eluting stent, which is intended to suppress tumor ingrowth through chemical changes in the membrane. Another modiﬁed stent is
the antireﬂux stent, which physically prevents the reﬂux of food by using an antireﬂux valve. Although the safety of these modiﬁed stents has been
demonstrated in both animal and human studies, their efﬁcacy, compared with conventional stents, remains unknown. Although the development of
these functional stents is challenging, their potential is promising. Effort is necessary to increase stent patency, which requires much modiﬁcation and
development, to prolong patient survival.
Copyright  2015, Society of Gastrointestinal Intervention. Published by Elsevier.
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Biliary stents have undergone various modiﬁcations, with the
goal of improving the management of both malignant biliary
obstruction and benign stenosis. New stent materials include
plastic stents and self-expanding metal stents (SEMSs); SEMSs can
be uncovered or covered. Moreover, various functional stents are
being developed to serve a diverse range of purposes, including
antimigratory stents, easily removable or shape-modifying stents,
antihyperplasia stents, drug-eluting stents (DESs), radioactive
stents, and bioabsorbable stents.1 These stents have been devel-
oped with the goal of improving stent patency through modiﬁca-
tions. This paper discusses DESs, which prevent tumor ingrowth
into the stent, and antireﬂux stents (ARSs), which suppress food
reﬂux.Drug-eluting stents
SEMSs can become obstructed by tumor ingrowth through the
stent mesh, tumor overgrowth at the proximal or distal end of the
stent, the compaction of biliary sludge or food, or mucosal hyper-
plasia due to stent-induced chronic inﬂammation.2,3 The use of
covered SEMSs cannot prevent tumor ingrowth completely,
although these stents were designed to suppress such ingrowth.
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contact with bile ﬂow.5,6 Degraded membranes form microcracks
and holes in the stent can result in tumor ingrowth and stent oc-
clusion.6,7 Given the limitations associated with the use of covered
SEMSs in the physical suppression of ingrowth, there have been
efforts to coat similar stents with antitumor drugs, to prevent
tumor invasion into the membrane and to prolong stent patency.
The results of animal and human studies of DESs are summarized in
Table 1.2,8–13 Antitumor agents used in drug-eluting stents include
hydrophobic paclitaxel and hydrophilic gemcitabine.Paclitaxel-eluting stent
The antitumor agent paclitaxel interferes with cell proliferation
in the G0/G1 and G2/M phases of the cell cycle, and triggers mo-
lecular signaling, via the mitochondrial pathway, causing cell
apoptosis.14–16 Paclitaxel causes the dose-dependent inhibition of
cell proliferation by human epithelial gallbladder cells, human ﬁ-
broblasts, and pancreatic carcinoma cells.14 This inhibitory effect,
observed in cell lines, has become the theoretical foundation for the
development of drug-eluting stents for use in malignant biliary
strictures.14 Lee et al8 developed a metallic stent covered with a
paclitaxel-incorporated membrane (MSCPM-I), i.e., a paclitaxel-
eluting SEMS, and the safety of this device was proven in the
porcine bile duct. Polyurethane membranes were eluted with threege of Medicine, Seoul, Korea
of Medicine, Seoul, Korea
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Table 1 Outcomes of Drug-eluting Metal Stent in Animal and Human Studies
Author (y) Type of
study
Comparison
groups (N)
Stent patency
(mean  SD)
Patient survival Stent occlusion (N, %) Complications (N, %)
Ingrowth Overgrowth Sludge Cholangitis Pancreatitis Migration
Lee et al8 (2005) Animal Paclitaxel
(MSCPM-I)
Animal
(Porcine)
NA NA Histology: epithelial denudation,
mucin hypersecretion,
epithelial metaplasia
No transmural necrosis
and perforation
Suk et al10 (2007) Human
(P)
Paclitaxel
(MSCPM-I)
Single arm
(n ¼ 21)
429 d
(range, 68–810)
350 d
(range, 68–811)
2 (9.5) 3 (1.6) 4 (1.9) 3 (1.4) 0 1 (0.4)
Lee et al9 (2009) Animal Paclitaxel
(PECMS)
Animal
(Canine)
NA NA Histology: minimal mucosal
hyperplasia in PECMS
No perforation
Song et al11 (2011) Human
(RCT)
Paclitaxel
(PECMS)
PECMS
(n ¼ 26)
Not different*
(P ¼ 0.307)
Not different*
(P ¼ 0.596)
5 (19.2) 0 0 3 (11.5) 1 (3.8) 0
CCMS
(n ¼ 26)
4 (15.3) 0 0 0 1 (3.8) 4 (15.3)
Jang et al2 (2013) Human
(RCT)
Paclitaxel
(MSCPM-I)
MSCPM-I
(n ¼ 60)
199.1  235.4 d 269.5  260.3 d 13 (22.4) 5 (8.6) 1 (1.7) 5 (8.6) 2 (3.5) 1 (1.7)
CCMS
(n ¼ 46)
148.7  98.8 d 181.9  116.8 d 9 (21.4) 2 (4.8) 2 (4.8) 1 (2.4) 4 (9.5) 0
Jang et al12 (2012) Animal Paclitaxel
(MSCPM-II)
Animal NA NA Histology: mucosal atrophy,
decreased wall thickness,
intestinal metaplasia
No transmural necrosis
and perforation
Chung et al13
(2012)
Animal Gemcitabine Animal NA NA Histology: Moderate to
severe inﬂammation,
ﬁbrous reaction
No transmural necrosis
and perforation
CCMS, conventional covered metal stent; MSCPM, metallic stent covered with a paclitaxel-incorporated membrane; NA, not available; P, prospective; PECMS, paclitaxel-
eluting covered metallic stent; RCT, randomized controlled trial; SD, standard deviation.
* Stent patency and survival time were not signiﬁcantly different between the two groups (PECMS and CCMS).
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three groups and then, surgically inserted into porcine bile ducts.
After 4 weeks, the segment of bile duct containing the stent was
examined histologically. Epithelial denudation, mucin hypersecre-
tion, and epithelial metaplasia were present in the bile ducts, but
transmural necrosis and perforation were not observed in any an-
imal. Another animal study also demonstrated the safety of
paclitaxel-eluting SEMSs.9 In that study, endoscopically inserted
paclitaxel-eluting covered metallic stents (PECMSs) and conven-
tionally covered metal stents (CMSs) were compared in canine bile
ducts. The PECMS group had mucosal hyperplasia and the stented
segments were signiﬁcantly thicker, these changes were not
observed in the CMS group. The histological changes associated
with the use of a paclitaxel-eluting stent are considered secondary
to mechanical irritation arising from the radial force of the stent
because the stent lumen is larger than the canine bile duct, and
local irritation due to paclitaxel itself. There were no cases of
perforation or necrosis of the bile duct. Through these animal
studies, paclitaxel-eluting SEMSs were established as the founda-
tion for developing a safe, new treatment modality for malignant
biliary obstruction.
Several human studies have followed these animal studies. A
multicenter single-arm pilot study using an MSCPM-I was the ﬁrst
such human study, enrolling 21 patients.10 The mean patency of an
MSCPM-I was 429 (median 270, range 68–810) days and the cu-
mulative patency rate at 3 months, 6 months, and 12 months was
100%, 71%, and 36%, respectively. This mean patency is longer than
that of other metal stents, and demonstrates the feasibility and
efﬁcacy of a MSCPM-I. Moreover, when the patients’ serum pacli-
taxel concentration was measured, the highest concentration was
seen between 1 and 10 days after stent insertion. Although a low
level of paclitaxel (0.015–0.20  101 mg/mL) was detected in the
blood samples of patients for over 50 days, the values were lower
than the therapeutic range of paclitaxel (0.9  10-4–1.1  101 mg/
mL). The presence of paclitaxel in the serum demonstrates that the
MSCPM-I provided a high local paclitaxel concentration at the
target tissue, including the bile duct and tumor, after which the
paclitaxel was released slowly into the systemic circulation. These
results provide evidence of the safety of such stents, from theperspective of the local application of an antitumor agent in DESs.
The MSCPM-I appeared to maximize the drug concentration in the
immediate tumor environment, while minimizing systemic expo-
sure and nontarget organ toxicity.
A prospective comparative study using an MSCPM-I found no
signiﬁcant differences between an MSCPM-I and a conventional
CMS, in terms of stent patency or patient survival.2 However, the
mean patency of the MSCPM-I might have been underestimated in
this study, because a substantial number of patients who received
an MSCPM-I died from disease progression before the stent was
blocked. Furthermore, the membranes of the stents (MSCPM-I and
CMS) used in the study consisted of a single polyurethane layer.
Polyurethanemembranes can be biodegraded by bile ﬂow resulting
in the formation of microcracks and holes in the stent. Conse-
quently, if themembrane is damaged by bile, it can be assumed that
the paclitaxel eluted in the membrane lacks sufﬁcient local anti-
tumoral effect to suppress tumor ingrowth. It is likely that this
limitation in the polyurethane membranes led to the lack of a dif-
ference in stent patency between the groups. A prospective pilot
study comparing PECMSs and CMSs, conducted by another group,
found no statistical differences in the duration of stent patency or
patient survival between the two groups.11 Although the two pro-
spective studies did not demonstrate superiority in terms of the
efﬁcacy of the paclitaxel-eluting stent, they did show its safety, and
reported acceptable complication rates in the human bile duct.
The MSCPM-II was developed to overcome the limitations of the
MSCPM-I and improve drug release.12 It is a double-layer drug-
eluting metal stent developed to overcome the limitations associ-
ated with polyurethane membranes. The inner polytetraﬂuoro-
ethylene (PTFE) layer is resistant to degradation by bile and the
outer polyurethane layer contains paclitaxel.12 In addition, the
MSCPM-II incorporated the surfactant Pluronic F-127 and poly-
urethane in the outer layer, to promote the steady release of
paclitaxel.12,17 In an animal study using the MSCPM-II, the histo-
logical changes in the porcine biliary epithelium consisted of an
inﬂammatory cell inﬁltrate and ﬁbrotic reaction, and were
considered acceptable in terms of safety.12 In the porcine serum
analysis, released paclitaxel was detected for 28 days with the 10%
Pluronic F-127 concentration.
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study of the newly developed MSCPM-II have not been published,
an interim analysis indicated that stent patency and survival time
did not differ signiﬁcantly between the MSCPM-II group and the
conventional CMS group (P ¼ 0.355 and P ¼ 0.570, respectively).
This study was terminated because of a high frequency of early
stent occlusion. Stent occlusion occurred in 35% (14/40) of the
MSCPM-II group and 21.9% (7/32) of the CMS group, with tumor
ingrowth occurring in one patient from each group. Stent occlusion
caused by sludge or food occurredwith a frequency of 28.3% (11/40)
in the MSCPM-II group and 18.8% (6/32) in the CMS group, and was
relatively higher than tumor ingrowth. The basic stent used in the
MSCPM-II was the Niti-S stent, ComVi type (Taewoong Medical,
Seoul, Korea), which had a high rate of stent occlusion (27.7%) in a
previous study.18 In that study, the causes of occlusion were tumor
overgrowth (4.25%), sludge (8.5%), and the impaction of food scraps
(14.9%). Since the MSCPM-II study was ended early because of early
stent occlusion, the efﬁcacy in terms of stent patency was not
evaluated.
Despite various modiﬁcations, there are no available data
related to the feasibility and efﬁcacy of a stent that incorporates an
antitumor agent; however, efforts to improve and demonstrate the
effectiveness of DESs are on-going. In terms of stent-coating, a
paclitaxel-eluting nanoﬁber-covered stent was developed.19 This
device uses an electrospinning method for drug deposition; drug
release is reported to be more effective than the existing dipping
method. The in vivo and in vitro feasibility of a nanoﬁber-covered
nonvascular stent was evaluated, and 30-day release of paclitaxel
was reported. The paclitaxel-eluting nanoﬁber membrane signiﬁ-
cantly inhibited the growth of CT-26 colon cancer, when compared
with paclitaxel injection. Histological examination demonstrated
that locally concentrated paclitaxel induced apoptosis at a higher
rate than the paclitaxel injection. Based on these results, the
paclitaxel-eluting nanoﬁber-covered stent should effectively sup-
press the ingrowth of cancer, and consequently improve stent
patency. However, the clinical feasibility of the use of a paclitaxel-
eluting nanoﬁber nonvascular stent for cholangiocarcinoma and
gastrointestinal cancers needs to be further examined.
The use of a drug-eluting membrane incorporating sodium
caprate, a drug-penetration enhancer, for the effective delivery of
drugs to tumor tissues is being actively studied at present.20 A
PTFE-covered DES was coated with a mixture containing sodium
caprate, paclitaxel, and polyurethane (PU), using the rolling coating
technique. This stent released paclitaxel for 2 months. In the
multilayered cell sheet model, the amount of penetrated paclitaxel
with the sodium caprate containing PU membrane was twice that
with the sodium caprate-free PU membrane. In addition, in a
tumor-bearing small animal model, the tissue penetration depth of
paclitaxel released from the sodium caprate containing PU mem-
brane was signiﬁcantly greater than with the sodium caprate free
PUmembrane. These results suggest that sodium caprate improves
the penetration and therapeutic efﬁciency of drugs in DESs, thereby
improving local stent therapy. Despite these efforts, no clinically
effective paclitaxel-eluting stent is available for clinical use.
The molecular and cellular alterations due to the anti-
proliferative effects of a paclitaxel-eluting membrane, implanted in
a pancreatic/cholangiocarcinoma tumor-bearing xenograft model,
were analyzed using western blotting, immunoprecipitation, and
immunoﬂuorescence.21 This demonstrated that paclitaxel, released
by diffusion from a paclitaxel-eluting membrane, suppressed
angiogenesis via the mammalian target of rapamycin and induced
apoptosis signaling pathways. This study described the molecular
mechanisms of DESs, and provided the basic theoretical back-
ground for the use of DESs. Although local treatment of malignant
biliary obstruction with paclitaxel-eluting metal stents ischallenging, there is no doubt that it is a promising treatment
modality. Further studies must develop a technique to maintain the
steady, effective release of the chemotherapeutic agent, over the
long-term, and to design other types of potent paclitaxel-eluting
metal stents.
Gemcitabine-eluting stent
Paclitaxel is a suitable drug for use in drug-eluting membranes,
due to its pharmacokinetic characteristics, which include its hy-
drophobic nature and rapid cellular uptake.21 However, gemcita-
bine is the standard chemotherapeutic agent in advanced
pancreatic and biliary tract cancer.22,23 Gemcitabine is hydrophilic
and its local delivery is difﬁcult due to the initial burst of the drug.
Consequently, efforts have been made to control this.24,25 Pullulan
is a natural polysaccharide that can be acetylated to varying de-
grees to form pullulan acetate, which has a greater drug-loading
capacity. When pullulan acetate was layered in PTFE and applied
as part of a gemcitabine-loaded controlled-release membrane for
drug-eluting nonvascular stents, gemcitabine was released for 30
days.24 Another preparation method involves the addition of a PU/
PTFE ﬁlm and gemcitabine to polymeric membranes with Polox-
amer 407 (PL, Lutrol F127, BASF). When these are eluted, gemcita-
bine forms crystals and the nanogranulated form of gemcitabine is
released from the PU/PTFE membrane.25 With this method, 70% of
the loaded gemcitabine was released within 35 days, which com-
pares favorably with 35% of the loaded gemcitabine being released
during the initial burst. Safety was proven in vitro and in vivo in
animal studies performed on porcine bile ducts, with a
gemcitabine-elutingmembrane that had been produced by another
research team, using a different method.13 A gemcitabine-eluting
SEMS composed of three layers was inserted surgically with gem-
citabine concentrations of 0%, 10%, 15%, and 20% (weight/volume).
Histological examinations performed 4 weeks later revealed
moderate to severe inﬂammation in the bile ducts in contact with
the stents containing 15% and 20% gemcitabine, but mild inﬂam-
mation was observed with 10% gemcitabine. Each of the groups
showed an equivalent response in terms of ﬁbrous reactions in the
submucosal layer. No transmural necrosis or perforation was
observed in any animal. In addition, serum from test animals
showed no abnormalities associated with gemcitabine. Therefore,
the safety of newly developed gemcitabine-eluting stents in normal
porcine bile ducts has been demonstrated, and it appears likely that
10% gemcitabine is appropriate for clinical application. However,
there have been no human clinical studies and so the safety and
efﬁcacy in humans have not been validated.
Anti-reﬂux metal stent
Stents inserted into the biliary tract can become obstructed by
biliary sludge, which consists of crystals of calcium bilirubinate and
calcium palmitate, as well as proteins, mucopolysaccharides,
cholesterol crystals, and bacteria.26,27 When a biliary stent is
inserted via the transampullary route, networks of large dietary
ﬁbers are formed due to duodenobiliary reﬂux; this intraluminal
framework plays an important role in the multifactorial process of
stent clogging.28 Accordingly, many studies have focused on
improving stent patency through use the of an antireﬂux biliary
stent, designed to suppress duodenobiliary reﬂux (Table 2).29–34
The ﬁrst attempt at development of such a stent was an antire-
ﬂux plastic stent, which was modiﬁed by attaching a windsock-
shaped tubular valve to the duodenal end of a conventional plas-
tic stent (10-F Tannenbaum stent; Cook Endoscopy, Winston-
Salem, NC).29 In a human study, the median patency of this anti-
reﬂux plastic stent was 145 (range 52–252) days, which was
Table 2 Outcomes of Antireﬂux Biliary Stent Including Plastic Stent and Metal Stent
Authors (y) Type of
study
Type of
stent
Comparison
groups (N)
Shape of valve Stent patency
(mean  SD)
Patient
survival
Complications
Cholangitis Sludge
occlusion
Pancreatitis Migration
Dua et al29
(2007)
RCT Plastic
stent
AR-PBS
(n¼ 30)
Windsock valve 145 d*
(range, 52–252)
NA 0 0 1 2
PBS (n¼ 30) 101 d
(range, 41–201)
NA 1 1 1 2
Hu et al30
(2011)
R SEMS Single arm
(n¼ 23)
Cross-shaped
outlet valve
14 mo 7.9 mo
(range, 1–14)
0 0 0 3
Kim et al34
(2013)
P SEMS Single arm
(n¼ 5)
Wine-glass-shaped
tubular valve
64 d (range, 4–235) NA 0 4 0 0
Lee et al32
(2013)
P SEMS Single arm
(n¼ 32)
S-type antireﬂux
valve
14.4 mo 8.5 mo
(range, 5.2–11.8)
0 6 0 0
Hamada et al33
(2014)
P SEMS Single arm
(n¼ 13)
Funnel-shaped
antireﬂux valve
NA NA 0 1 0 4
Hu et al31
(2014)
RCT SEMS pcARMS
(n¼ 56)
Nipple shape
antireﬂux valve
13.0  3.4 moy 8.0  1.3 mo 10 2 2 5
ucSEMS
(n¼ 56)
10  1.2 mo 9.0  0.8 mo 21 2 2 1
AR-PBS, antireﬂux plastic biliary stent; NA, not available; P, prospective; PBS, plastic biliary stent; pcARMS, partly covered antireﬂux metal stent; R, retrospective; RCT,
randomized controlled trial; SEMS, self-expandable metal stent; SD, standard deviation; ucSEMS, uncovered SEMS.
* The median patency of the AR-PBS was signiﬁcantly longer than that of PBS (P ¼ 0.002).
y The median patency of the pcARMS was signiﬁcantly longer than that of ucSEMS (P ¼ 0.044).
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conventional plastic stents.
In a barium imaging study, when an SEMS was placed through
the main duodenal papilla, the reﬂux of duodenal contents
occurred in all patients.35 Subsequently, many studies have exam-
ined SEMSs with antireﬂux functions. The ﬁrst antireﬂux SEMSs
sought to achieve reduced duodenal biliary reﬂux and improved
bile drainage by attaching a hemispheric silicon valve with a cross-
shaped outlet to the distal (duodenal) end of the stent.30 In a
retrospective pilot study of this antireﬂux SEMS in 23 patients, the
median duration of stent patency was 14 months, with cumulative
patency rates at 3 months, 6 months, and 12 months of 95%, 74%,
and 56%, respectively. There were no biliary symptoms, except for
six stent malfunctions associated with tumor ingrowth (one pa-
tient), tumor overgrowth (two patients), and stent migration (three
patients). In a randomized trial conducted by the same research
team,31 the cross-shaped outlet was modiﬁed into a small cross-
type oriﬁce and the valve was developed to protrude from the
papilla into the duodenum to prevent the ascending reﬂux of
enteric contents; this valve shape collapses with increased intra-
bowel pressure without the valve impairing the antegrade bile
ﬂow. In a prospective study of 112 patients, cholangitis was sta-
tistically signiﬁcantly less frequent in the antireﬂux SEMS group,
compared with the control group (10 versus 21 patients; P¼ 0.035).
The median stent patency was also signiﬁcantly longer in the
antireﬂux SEMS group than the control group (13.0  3.4 versus
10.0  1.2 months; P ¼ 0.022). Combined, these studies indicate
that stenting with an antireﬂux SEMS, compared with a standard
SEMS reduces the risk of ascending cholangitis, and is associated
with longer stent patency.30,31 In studies of antireﬂux SEMSs with
various valve shapes, the antireﬂux SEMSs showed greater clinical
efﬁcacy that seen in the controls.32,33 Uncovered metal stents with
an S-type antireﬂux valve had a relatively long median stent
patency of 14.4 months, but were unable to prevent sludge for-
mation completely.32 Ten of the 32 patients who received a stent
experienced stent occlusion, including six cases of occlusion caused
by sludge compared with four cases of occlusion caused by tumor
ingrowth. However, since the antireﬂux valve reduced duodeno-
biliary reﬂux, resulting in no episodes of ascending cholangitis or
acute pancreatitis, its technical feasibility and safety were proven.
In a pilot study using a CMS with a 10-mm-long funnel-shapedantireﬂux valve in 13 participants, stent occlusion caused by
sludge was seen in only one participant, although other causes of
stent occlusion were observed.33 The patency of this antireﬂux
stent was signiﬁcantly longer than prior SEMSs (median, not
available versus 58 days; P ¼ 0.039). Although these studies
showed the feasibility of an antireﬂux stent, others have reported
negative results, apparently related to the design of the antireﬂux
valve. A prospective study of a SEMS with a wine glass-shaped
tubular valve resulted in early termination, as stent occlusion
fromvalve malfunction, due to sludge impaction or a clog, occurred
in four of ﬁve patients within 1 month.34 This study showed that
the function of the antireﬂux stent could be determined by the
degree of hydrophilic coating, the ratio of the diameter of the valve
to that of the stent, and the shape of the antireﬂux valve used.
Although various attempts have been made to prevent duodeno-
biliary reﬂux after SEMS insertion, a stent that can prevent reﬂux
completely has not yet been developed. A challenge in the devel-
opment of an antireﬂux stent is that in vitro success does not
guarantee success in humans. This is because multiple factors,
including tumor biology, the types of food consumed by the patient,
and the patient’s lifestyle, act together on the stent to cause oc-
clusion. Although these factors cannot be prevented completely,
the efﬁcacy is expected to improve as the design of the antireﬂux
valve is improved.
Conclusion
Modiﬁcations of the stents used inmalignant biliary obstruction
are designed to increase stent patency; DESs and ARSs are examples
of such modiﬁcations. A DES chemically suppresses stent ingrowth
via antitumor agents, while an ARS prevents food reﬂux mechani-
cally with the use of an antireﬂux valve, with both types increasing
stent patency. The DES was developed from a metal stent that was
eluted with hydrophobic paclitaxel or hydrophilic gemcitabine.
Although its safety has been indicated by animal and human
studies, its efﬁcacy in terms of stent patency, in comparison with
conventional stents, has yet to be demonstrated. However, it is
expected that a DES with increased stent patency will be developed
in the future, through the development of various surfactants and
drug enhancers, stent structure modiﬁcations, and improvements
in stent materials, metal surface treatments, drug coating
Gastrointestinal Intervention 2015 4(1), 50–5454techniques, and polymer types. The ARS has shown conﬂicting re-
sults based on valve shape. Studies have reported varying efﬁcacies,
and its clinical efﬁcacy has not yet been established due to a lack of
large-scale prospective studies. There are limitations in prolonga-
tion of stent patency only by modiﬁcations of the stents because a
stent is basically a foreign body in human body. However, a new
therapeutic paradigm using functional stents suitable for speciﬁc
purposes will be established. Efforts at developing functional stents
with improved stent patency, and therefore increased patient sur-
vival, should be continued.
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